Novo Nordisk releases 2025 financial report: Semaglutide sales reach 228.288 billion Danish kroner

K-LinePoet · 2026-02-10T14:52:18+00:00

Novo Nordisk releases 2025 financial report, with total annual sales of 309.1 billion Danish kroner, a 10% year-over-year increase. The sales of semaglutide drugs reached 228.288 billion Danish kroner, including Ozempic sales of 127.089 billion, Wegovy sales of 79.106 billion, and NovoNorm sales of 22.093 billion. Since its launch on January 5, Wegovy tablets have reached a weekly prescription volume of 50,000.

K-LinePoet

2026-02-10 14:52:18

Abstract generation in progress

According to Morningside AI News, Novo Nordisk released its 2025 financial report on February 4. The company’s full-year sales reached 309.1 billion Danish kroner, a 10% increase at fixed exchange rates. The total annual sales of all semaglutide medications amounted to 228.288 billion Danish kroner. The sales of the diabetes version of semaglutide injection Ozempic (domestic brand name NovoThain) reached 127.089 billion Danish kroner, while the weight-loss version of semaglutide injection Wegovy (domestic brand name NovoYing) totaled 79.106 billion Danish kroner. The oral tablet of the diabetes version of semaglutide (domestic brand name NovoXin) was 22.093 billion Danish kroner. Since its U.S. launch on January 5, the Wegovy tablet (once daily oral semaglutide 25mg) has accumulated approximately 50,000 prescriptions weekly.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.